Table 1 Observed EuroQol utility values and days of follow‐up, by year in trial.

Assessment period	SCSC		ATH
	n	Mean (SD; 95% CI; range) utility	n	Mean (SD) utility (95% CI; range)
Baseline	228	0.60 (0.21; 0.58 to 0.64; −0.18 to 1)	232	0.57 (0.23; 0.54 to 0.60; −0.18 to 1)
12 Months	217	0.57 (0.25; 0.54 to 0.61; −0.18 to 1)	226	0.54 (0.27; 0.51 to 0.59; −0.28 to 1)
24 Months	207	0.56 (0.25; 0.53 to 0.60; −0.24 to 1)	211	0.54 (0.27; 0.51 to 0.58; −0.24 to 1)
36 Months	195	0.57 (0.24; 0.51 to 0.58; −0.13 to 1)	199	0.54 (0.27; 0.50 to 0.58; −0.18 to 1)

ATH, aggressive treatment delivered in hospital; SCSC, symptom control delivered by shared care.